ABBV-466 posts a higher Crohn’s remission rate than Skyrizi alone
AbbVie’s next-generation Crohn’s disease strategy has moved beyond theoretical combination logic and into measurable endoscopic benefit. In a 300-patient phase 2 trial, the company’s dual-target regimen, code-named ABBV-466, produced an endoscopic remission rate of 30.2% at Week 12, exceeding both arms used for comparison: 21.3% with Skyrizi alone and 18.0% with trosunilimab monotherapy.
The result matters because Crohn’s disease rarely behaves as a single-pathway illness. Even when interleukin-23 blockade calms one inflammatory axis, residual trafficking of immune cells through α4β7-mediated pathways can keep intestinal injury smoldering. AbbVie’s approach directly tests that biology by layering an α4β7 inhibitor onto its commercially successful IL-23 antagonist, asking whether two partially complementary mechanisms can quiet mucosal inflammation more completely than either drug can do alone.
The answer, at least in this midphase readout, is yes.
Dual-pathway blockade was designed to close a biologic gap
Skyrizi has already become one of AbbVie’s most important assets, generating $10 billion over the first half of the year. Even so, the company identified a mechanistic weakness in the IL-23 strategy: evidence of α4β7-driven inflammation persisted despite IL-23 inhibition. That biological observation set up the combination hypothesis behind ABBV-466.
This is not a cosmetic reformulation of an existing drug. It is a deliberate attempt to suppress two immune signals that contribute to intestinal inflammation from different angles. IL-23 blockade reduces inflammatory T-cell activity, while α4β7 inhibition interferes with lymphocyte trafficking into the gut. In Crohn’s disease, where patchy transmural inflammation can survive partial control and continue to erode the mucosal barrier, that dual mechanism offers a plausible path to deeper healing.
AbbVie randomized 300 people with moderate-to-severe Crohn’s disease to Skyrizi, trosunilimab, or the combination. At Week 12, the combination arm led the field on the study’s primary endpoint of endoscopic remission. The monotherapy numbers were lower in both comparator groups, suggesting that the two-target strategy may produce more complete suppression of visible intestinal disease than either component alone.
The patient mix was harder than in prior Skyrizi studies
Cross-trial comparisons should be handled carefully, but the context still matters. AbbVie’s phase 2 population included 75% of patients who had failed at least one advanced therapy, while the remaining 25% were biologic-naïve. That matters because patients with prior treatment failure often present a more refractory inflammatory burden and are less likely to achieve endoscopic remission on a single mechanism alone.
The comparator trials for Skyrizi were not identical. In one phase 3 study that reported a 24% endoscopic remission rate, some biologic-naïve patients were included. Another phase 3 trial, limited to people with prior biological failure, reported a 19% remission rate. The new ABBV-466 study also included patients with prior exposure to other advanced therapies that were not available when the Skyrizi monotherapy program was completed, which makes the current cohort a better reflection of today’s treatment-experienced Crohn’s population.
Among those with prior biological failure in the ABBV-466 study, 9.3% had previously received an IL-23 therapy and 12% had tried a JAK inhibitor. AbbVie’s Rinvoq, the first FDA-approved JAK inhibitor for moderate-to-severe Crohn’s disease, entered the market after the Skyrizi monotherapy trials ended. The result is a population that has seen more therapeutic classes, more failures, and more immune escape before reaching this trial.
Epithelial repair and tissue remodeling appeared after treatment
The clinical signal was not limited to the endoscopic score. AbbVie linked ABBV-466 to colonic epithelial repair and barrier restoration by Week 12, with tissue remodeling and metabolic changes emerging by Week 24 that were generally absent in either monotherapy arm. Those findings are biologically coherent. Once inflammatory trafficking is interrupted and cytokine pressure recedes, epithelial restitution can proceed, tight junctions may stabilize, and the gut wall has a better chance to recover some structural integrity.
In Crohn’s disease, mucosal healing is more than a cosmetic endpoint. Persistent epithelial injury keeps the immune system exposed to luminal antigens and bacterial products, sustaining the cycle of inflammation. A treatment that improves both visible ulceration and the tissue-level repair environment may offer a more durable therapeutic foothold than one that only suppresses symptoms or reduces inflammatory markers in isolation.
Safety findings stayed broadly similar across arms
The safety profile did not show a dramatic divergence between groups. Serious adverse event rates were similar across the three cohorts, which is reassuring for a regimen that increases biologic complexity rather than simply substituting one mechanism for another. In the ABBV-466 and trosunilimab groups, the most common adverse events were Crohn’s disease and nausea. In the Skyrizi monotherapy arm, Crohn’s disease and joint pain were the most common adverse events.
For clinicians, the safety story is important because combination immunotherapy in inflammatory bowel disease can trigger concern about additive toxicity, infection risk, or tolerability problems that could erase any efficacy gain. No such signal emerged in this initial readout. The absence of a major safety penalty keeps the discussion centered on efficacy and patient selection rather than on whether the regimen can be administered at all.
AbbVie is already moving the program into a larger phase 2 test
AbbVie began a larger phase 2 study of the combination in July. The new trial enrolls 2,000 patients and includes two substudies, one evaluating ABBV-466 in moderate-to-severe Crohn’s disease or ulcerative colitis. The scale of that program suggests AbbVie is treating the phase 2 signal as more than a preliminary curiosity.
Roopal Thakkar, M.D., AbbVie’s Chief Scientific Officer, indicated during an earnings call that the company does not plan to wait for final results before deciding whether to advance. Interim snapshots are already built into the development plan, and higher efficacy with the higher trosunilimab dose would prompt preparation for phase 3 development of the combination. That approach fits a company with a strong Crohn’s franchise and a clear incentive to extend the life of an established mechanism by pairing it with a second pathway.
The next readouts will need to answer a harder question than the one this phase 2 trial addressed: whether the early mucosal benefit can persist in a broader, more heavily treated population and justify a coformulated product strategy. For now, ABBV-466 has done what midphase data are supposed to do. It has shown a biologically coherent advantage over a successful single agent without adding an obvious safety burden, and it has pushed the Crohn’s program into a larger, more consequential test.